Q-omics provides the consensus-scored AMY1A profile across patient tissues and cancer cell-line models. AMY1A expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AMY1A is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, AMY1A RNA expression shows 5,292 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, ESCA, and BRCA as cancer lineages where AMY1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMY1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMY1A survival associations across molecular data types. AMY1A RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMY1A RNA expression–survival associations across cancer types. High AMY1A expression shows unfavorable associations in UVM, UCS, LUSC and PAAD, but favorable associations in STAD and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AMY1A RNA expression.
This table summarizes AMY1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for AMY1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMY1A shows lower tumor expression in LUSC and higher tumor expression in ESCA. The ESCA box plot shows higher AMY1A RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .037).
This table shows molecular features associated with AMY1A in patient tissues and cancer cell lines. In patient samples, AMY1A shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, AMY1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
